Abbreviations: Concomitant tumor resistance (CTR), magnetic resonance imaging (MRI), Bioluminescence (BLI), fluorescence-activated cell sorting (FACS), fetal bovine serum (FBS), green fluorescent protein (GFP), standard error of the mean (SEM), micron-sized paramagnetic iron oxide (MPIO) Dormant cancer cells, also referred to as quiescent, slowly cycling or "nonproliferative" cells, are believed to contribute to tumor recurrence and present a therapeutic problem because they are nonresponsive to current therapies that target proliferating cells. Concomitant tumor resistance (CTR) is the ability of a primary tumor to restrict the growth of secondary metastases. In this paper, we investigate these 2 cancer concepts using cellular magnetic resonance imaging (MRI). A new model for CTR is presented where a primary mammary fat pad tumor is generated using a human breast cancer cell line (231) and breast cancer brain metastases are generated using a cell line derived from 231 to be brain metastatic (231-BR). Iron oxide particles are used to label the 231BR cells to allow for tracking of the proliferating cells, which form metastases, and the nonproliferating cells, which remain dormant in the brain. Bioluminescence and fluorescence-activated cell sorting are used to validate the MRI data. The presence of a primary 231 mammary fat pad tumor inhibited the formation of MRIdetectable 231BR brain metastases. More iron-retaining cells persisted in the brains of mice with a primary tumor. Bioluminescence and fluorescence-activated cell sorting provide evidence that signal voids detectable by MRI on day 0 represent live, iron-labeled cells in the brain. This work shows that retention of iron by nonproliferative cancer cells can be exploited to monitor the fate of this important cell population in vivo, and it points to a new mechanism for CTR, the enhancement of dormancy by a primary tumor.
INTRODUCTION
Metastasis, the dissemination of cancer cells from the primary tumor and growth at secondary sites, is the major cause of mortality in patients with cancer and may occur years after successful removal of the primary tumor and adjuvant therapy. Dormant cancer cells, also referred to as quiescent, slowly cycling or ЉnonproliferativeЉ cells, are believed to contribute to tumor recurrence (1) (2) (3) . Clinical dormancy is reflected by relapses at distant sites after the original primary cancer diagnosis and remission. Dormant cancer cells also present a substantial therapeutic problem because they are quiescent and thus are nonresponsive to current therapies that only target proliferating cells (4) (5) (6) . For many individuals, cancer may become dormant and not progress, while only in some, will it become a symptomatic disease. Discerning the mechanisms that either maintain prolonged cellular dormancy or activate dormant cells to a proliferative state has been a goal of scientists worldwide. However, relatively little is known about dormant cancer cells, and studying these cells is challenging, as, at present, there are few suitable in vivo assays.
The time to transition between dormancy and active metastatic growth may be governed by local (microenvironment) or systemic mechanisms. Concomitant tumor resistance (CTR) is the ability of a primary tumor to systemically restrict the growth of secondary distant metastases (7, 8) . CTR has been described in human and animal systems, and it can be generated by both immunogenic and nonimmunogenic primary tumors (9) . The relevance of CTR has been highlighted by numerous observations showing that the removal of human and murine tumors can be followed by an abrupt increase in metastatic growth, suggesting that a primary tumor may exert a controlling action on metastases (10) . The following 3 potential mechanisms are usually cited for CTR, the primary tumor may:
(1) Prime the immune system to assist clearance of metastatic cells. (2) Restrict the growth of distant metastases through production of antiangiogenic molecules. (3) Systemically deplete essential host factors, preventing the growth of any other tumors (athrepsia) (11) .
The proliferative status of cancer cells can be interrogated in vivo using cellular magnetic resonance imaging (MRI). Cellular MRI uses magnetic agents to label specific cells, enhancing their detectability (12) . The most widely used agents are iron oxide nanoparticles (13) . The presence of iron in cells causes a distortion in the magnetic field and leads to signal loss in ironsensitive images. Cells appear as discrete black regions. Even single iron-labeled cells could be detected using MRI (14, 15) . Few groups have used iron nanoparticles and MRI to track cancer cells. This is because the iron nanoparticles are diluted over time in dividing cells, leading to loss of signal and therefore loss of cell detection. However, we, and others, have shown that the retention of iron particles in nonproliferative, or slowly cycling, cancer cells can be exploited to detect particular cancer cell populations (16) (17) (18) . In this paper, we use cellular MRI to study CTR in a novel model of breast cancer metastasis to the brain.
METHODS

Cell Culture
Human breast cancer cells (MDA-MB-231) were purchased from ATCC (Manassas, Virginia). Human brain metastatic breast cancer cells (MDA-MB-231-BR), previously transduced with enhanced green fluorescent protein, were a kind gift from Dr. Patricia Steeg's laboratory at the National Cancer Institute (Bethesda, Maryland) (19) . Cells were grown in Dulbecco's Modified Eagle's Medium containing 10% fetal bovine serum (FBS), 1% antibiotics, and 0.375 mg/mL zeocin. For tracking cells in the brain by MRI, MDA-MB-231-BR cells were labeled with iron oxide nanoparticles (0.9 m micron-sized paramagnetic iron oxide [MPIO] , 62% magnetite, labeled with Flash Red; Bangs Laboratory, Fishers, Indiana) as previously described (20) . Cell viability was measured by trypan blue exclusion and was not significantly different from previous experiments using unlabeled cells. Perl's Prussian Blue-stained cells were analyzed to evaluate iron labeling efficiency. The cell lines were tested for mycoplasma contamination using the MycoAlert Mycoplasma Detection Kit (Lonza, Rockland, Maine) and were found to be negative. To detect MDA-MB-231BR cells with bioluminescence imaging (BLI), cells were transduced using RediFect Red-Fluc-GFP lentiviral particles (Perkin-Elmer) at a multiplicity of infection of 50. After transduction, the cells underwent 2 rounds of fluorescence-activated cell sorting (FACS) to select for the top 5% green fluorescent protein (GFP)ϩ expressers.
Experimental Animals
In this study, 6-to 8-week-old female nude mice (nu/nu; Charles River Laboratories, Wilmington, Massachusetts) were housed in a barrier facility. Experiments were approved by the Animal Use Subcommittee of the University Council on Animal Care at the University of Western Ontario. Four groups of mice were studied. Mice in groups 1 and 2 (n ϭ 8/group) received an injection of either vehicle (Hank's Balanced Salt Solution; group 1) or 500 000 unlabeled MDA-MB-231 cells (group 2) in the lower right mammary fat pad. The primary mammary fat pad tumors were allowed to grow for 15 days in group 2 at which time mice in groups 1 and 2 received an intracardiac injection of 175 000 ironlabeled MDA-MB-231-BR cells suspended in 0.1 mL of Hank's Balanced Salt Solution. All injections were performed while under anesthesia induced by isoflurane (2%). Mice in groups 3 (n ϭ 3) and 4 (n ϭ 2) received only MDA-MB-231BR cells via intracardiac injection and were used for BLI and FACS, respectively.
MRI
MRI was performed using a 3.0 T GE Excite MR750 clinical scanner (General Electric, Mississauga, Ontario, Canada), with a custom insertable gradient coil and a custom mouse head radiofrequency coil. Isoflurane anesthesia was used during scans, and the temperature was maintained with warm saline bags. Images were acquired using a 3-dimensional balanced steady-state free precession pulse sequence with spatial resolution ϭ 100 ϫ 100 ϫ 200 m and scan time ϭ 35 minutes for brain imaging and spatial resolution ϭ 200 ϫ 200 ϫ 200 m and scan time ϭ 30 minutes for body imaging. Images of the mouse brain were obtained on the day of the intracardiac injection to evaluate the initial arrest of cells in the brain and at the endpoint to evaluate metastatic growth and quantify the number of residual signal voids; the endpoint was day 30 after intracardiac injection. For group 2, the mouse body was also imaged at endpoint to eval- uate the mammary fat pad tumor growth. Mice were euthanized by pentobarbital (Euthanyl) overdose after the final imaging session. Tissues were formalin-fixed, paraffin-embedded and sectioned with image guidance. Hematoxylin and eosin staining was used to visualize basic morphology. Figure 1 illustrates the imaging experiments.
Magnetic Resonance Image Analysis
Brain images were assessed for regions of signal loss because of the presence of iron-containing cells, and regions of high signal representing metastases. To assess whether the primary mammary fat pad tumor has an effect on the growth of metastases, the number of tumors in the whole brain was counted and the volume of each metastasis was measured. To assess whether the presence of a primary tumor influences the number of nonproliferative cancer cells in the brain, the number of discrete signal voids in 50 evenly spaced MRI slices was counted.
Image analysis was performed using open-source OsiriX image software (version 3.9.2). Brain metastases were manually counted and segmented in each of the image slices per mouse. The region-of-interest volume tool was used to calculate the tumor volume. Statistical analysis was performed using GraphPad Prism version 6.0 software (GraphPad, San Diego, California). Twoway unpaired Student t-tests were used to compare 2 groups at a single time point. Data are presented as mean and standard error of the mean (SEM).
BLI
Group 3 mice (n ϭ 3) received an intracardiac injection of 50 000 iron-labeled luciferase-positive MDA-MB-231-BR cells for day 0 BLI. BLI was performed on a hybrid optical/Xray scanner (IVIS Spectrum animal imager, Xenogen, Alameda, California) on 3 mice within 1 hour after intracardiac injection of iron-labeled MDA-MB-231-BR cells. Mice were anesthetized with isoflurane (2% in 100% oxygen) using a nose cone attached to an activated carbon charcoal filter for passive scavenging. Mice received 150 L of D-luciferin (30 mg/mL) intraperitoneally, and BLI images were captured every 1-5 minutes for up to 30 minutes.
Flow Cytometry
Group 4 mice (n ϭ 2) received an intracardiac injection of 500 000 iron-labeled MDA-MB-231-BR cells, as described above. The brains of these mice were imaged with MRI to confirm the presence of signal voids in the brain indicative of a successful intracardiac injection. Mice were sacrificed 1-day post cell delivery by a pentobarbital (Euthanyl) overdose. After sacrifice, mice were perfused with a 0.9% saline solution and the brains were immediately excised. Individual mouse brains were dissociated using a Papain Dissociation System (Worthington Biochemical Corporation, Lakewood, New Jersey) according to the manufacturer's instructions. After dissociation, the resulting cells from 2 mouse brains were pooled and then MPIO-containing cells were concentrated using an EasySep® magnet (STEMCELL Technologies Inc., Vancouver, British Columbia, Canada). The isolated concentrate was resuspended in 1% FBS in phosphate-buffered saline and was then analyzed for live GFPϩ Flash Redϩ-containing cells by FACS. To determine viability, cells were stained with 7-aminoactinomycin D viability dye (ThermoFisher Scientific, Waltham, Massachusetts) for 20 minutes on ice before sorting. FACS was conducted on a FACSAriaIII system (BD Biosciences, San Jose, California) using a 100-m filter and normal dissociated mouse brain was used as a negative control. Live (7-aminoactinomycin-negative) GFPϩ Flash Redϩ cells were collected in 100% FBS and transferred to DMEM containing 10% FBS for in vitro expansion. FlowJo© software (Tree Star Inc., Ashland, Oregon) was used to analyze FACS data.
RESULTS AND DISCUSSION
All mice developed MRI-detectable brain metastases. The average volume of the brain metastases was not significantly different in group 1 or 2. All mice in group 2 developed mammary fat pad tumors. Brain metastases were visualized as regions of signal hyperintensity in balanced steady-state free precession images. Fewer brain metastases developed in mice with a primary mammary fat pad tumor. Figure 2 shows representative mouse brain images with metastases and analysis of the mean number of brain metastases per group. The mean number of MRI-detectable brain metastases counted was 37.4 (Ϯ6 SEM) for group 1 mice and 7.8 (Ϯ1.6 SEM) for group 2 mice. These results indicate that a primary mammary fat pad tumor can inhibit the development of brain metastases. To the best of our knowledge, this is the first report of a mouse model where a parental breast tumor and brain metastatic clone is used in the same animal and the first such model for studying CTR.
Signal voids, representing iron-labeled cancer cells, were observed in the mouse brains on the day of the injection and at endpoint. These appear as discrete regions of signal loss throughout the brain. On the day of the intracardiac injection, images showed that there was no significant difference in the number of voids in the brain for groups 1 and 2. The mean number of voids counted from day 0 images was 183 (Ϯ15.7 SEM) for group 1 and 217 (Ϯ22.1 SEM) for group 2. In the endpoint images, however, significantly more voids persisted in the brains of mice that also had a primary mammary fat pad tumor. The mean number of voids counted from day 30 images was 26.5 (Ϯ4.5 SEM) for group 1 and 101 (Ϯ7.5 SEM) for group 2. Representative mouse brain images and an analysis of the number of signal voids and the percentage of voids retained in the brain are shown in Figure 3 . This finding suggests that the presence of a primary breast tumor can enhance the persistence of iron-retaining MDA-MB-231-BR cancer cells in the brain and points to a possible new mechanism for CTR.
Previous work with each cell line, MDA-MB-231 and MDA-MB-231BR, in separate model systems has provided evidence for (Figure 3B) shows signal in the brain. FLuc BLI requires adenosine triphosphate as a cofactor and therefore the BLI signal is only detected from live cells (21) . Together, these images provide proof that the signal voids detectable by MRI on day 0 represent live, luciferase-positive cells in the brain.
FACS was used to successfully isolate live cells that were GFPϩ and red fluorescent (red MPIO) from the brains of mice that were injected with 500 000 GFPϩ iron-labeled 231BR cells ( Figure 5) . MRI confirmed the successful delivery of MPIOlabeled cells to the mouse brain ( Figure 5, A and B) . Brains from 2 mice that had successful cell delivery were isolated, and dissociated cells were pooled for FACS analysis. A total of 5.1 ϫ 10 6 cells were analyzed after concentration by magnetic column. The majority of these cells were likely normal brain cells from the whole brain dissociation; however, FACS analysis identified and isolated 2.9 ϫ 10 3 live GFPϩ Flash Redϩ cells ( Figure 5C ). GFPϩ Flash Redϩ cells were found only in the brains of mice that had received MPIO-labeled 231BR cell injections, naïve mouse brain exhibited no GFPϩ or Flash Redϩ cell populations. The identified GFPϩ Flash Redϩ cells were collected and expanded in vitro. The majority (ϳ90%) of isolated cells adhered to tissue culture plastic and successfully expanded, displaying the same cell morphology as the original cultured 231BR cells (data not shown). Because the cancer cells were GFPϩ and the iron particles were Flash Red-labeled, these FACS data provide additional support for our claim that signal voids in magnetic resonance images represent viable iron-positive cancer cells. We acknowledge that there is the potential for the iron from labeled cells to be transferred to phagocytic cells if they die and that this bystander cell labeling may lead to misinterpretation of the MRI signal voids as the original ironlabeled, injected cancer cells. Future FACS work will investigate other cell types in the brain to determine if other cell types are positive for the iron label and the relative percentages of cancer cells versus noncancer cells that are red fluorescent and, if possible, the relative iron content.
Ruggiero et al. have identified a molecular basis for CTR that involves 2 serum factors (meta-and ortho-tyrosine isomers), released by highly metabolic primary tumors, which suppress metastasis formation. They show that the antitumor effects are mediated, in part, by early inhibition of the mitogen-activated protein/extracellular-signal-regulated kinase pathway and inactivation of STAT3, potentially driving tumor cells into a state of dormancy (22) . Our work also suggests that a primary tumor may enhance cancer cell dormancy as a mechanism for the inhibition of metastasis formation. Future studies will focus on evaluation of the cell cycle status on iron-retaining cancer cells and serum factors, which may be involved in the MRI observations, to provide additional information on these potential mechanisms.
